ENSC catalyst calendar

Ensysce Biosciences, Inc.

Upcoming catalysts
2
Cash runway
0.6 months
Cash & investments
$1M
Phase 3 programs
1

Ensysce Biosciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 0.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 7 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 13, 2026 est. Next quarterly earnings (projected) Earnings —
December 22, 2026 Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) Trial Milestone Phase 1

Track ENSC alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ENSC in the tracker

Recent history

DateEventTypePhase
August 25, 2026 8-K filed: Other event Filing —
August 24, 2026 8-K filed: Other event Filing —
August 15, 2026 PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) Trial Milestone Phase 3
August 13, 2026 Quarterly results filed (8-K) Earnings —
August 6, 2026 8-K filed: Material agreement, Acquisition completed, Leadership change, Reg FD disclosure Corporate —
July 15, 2026 8-K filed: Leadership change Corporate —
May 22, 2026 8-K filed: Listing / standard notice Corporate —
May 15, 2026 Quarterly results filed (8-K) Earnings —
April 8, 2026 8-K filed: Material agreement, Other event Corporate —
April 3, 2026 8-K filed: Leadership change Corporate —
March 30, 2026 8-K filed: Leadership change Corporate —
March 30, 2026 Quarterly results filed (8-K) Earnings —
February 27, 2026 8-K filed: Listing / standard notice Corporate —
November 17, 2025 8-K filed: Material agreement, Other event Corporate —
November 14, 2025 Quarterly results filed (8-K) Earnings —
August 13, 2025 Quarterly results filed (8-K) Earnings —
May 13, 2025 Quarterly results filed (8-K) Earnings —
April 24, 2025 8-K filed: Material agreement, Other event Corporate —
November 14, 2023 Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201) Trial Milestone Phase 2
April 26, 2023 Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101) Trial Milestone Phase 1
December 23, 2022 A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104) Trial Milestone Phase 1
August 31, 2022 A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103) Trial Milestone Phase 1
March 21, 2022 Evaluation of Oral PF614 Relative to OxyContin (PF614-102) Trial Milestone Phase 1
November 11, 2020 Oral Nafamostat in Healthy Volunteers (NAF-101) Trial Milestone Phase 1
January 18, 2018 Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101) Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.